Publication date: Available online 12 June 2016
Source:Journal of Oral and Maxillofacial Surgery
Author(s): Lindsay L. Graves, Susan V. Bukata, Nona Aghazadehsanai, Tina I. Chang, Neal Garrett, Arthur H. Friedlander
PurposeThe risk of developing concomitant medication-related osteonecrosis of the jaw (MRONJ) among patients who have sustained an atypical femoral fracture (AFF) in association with parental administration of a bisphosphonate osteoclastic inhibitor medication for malignant disease is unclear. We search the published data to determine the prevalence of these concomitant adverse medication events, if any.Materials and MethodsA systematic review of published case series in the PubMed data base was undertaken to ascertain the prevalence of patients having a concomitant history of AFF and MRONJ. The data were analyzed to provide prevalence rates of these events from the literature.ResultsTwo case series were identified which delineated the risk (25% and 33%, respectively) of concomitant development of MRONJ and AFF among recipients of parenteral bisphosphonate medication administered for malignant disease.ConclusionThe published data suggest that approximately 30% of patients receiving parenteral bisphosphonates and having sustained an AFF may go on to develop comorbid MRONJ.
Source:Journal of Oral and Maxillofacial Surgery
Author(s): Lindsay L. Graves, Susan V. Bukata, Nona Aghazadehsanai, Tina I. Chang, Neal Garrett, Arthur H. Friedlander
PurposeThe risk of developing concomitant medication-related osteonecrosis of the jaw (MRONJ) among patients who have sustained an atypical femoral fracture (AFF) in association with parental administration of a bisphosphonate osteoclastic inhibitor medication for malignant disease is unclear. We search the published data to determine the prevalence of these concomitant adverse medication events, if any.Materials and MethodsA systematic review of published case series in the PubMed data base was undertaken to ascertain the prevalence of patients having a concomitant history of AFF and MRONJ. The data were analyzed to provide prevalence rates of these events from the literature.ResultsTwo case series were identified which delineated the risk (25% and 33%, respectively) of concomitant development of MRONJ and AFF among recipients of parenteral bisphosphonate medication administered for malignant disease.ConclusionThe published data suggest that approximately 30% of patients receiving parenteral bisphosphonates and having sustained an AFF may go on to develop comorbid MRONJ.
from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1ZKxlfK
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου